Buprenorphine in Neonatal Abstinence Syndrome

Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long‐acting opioid with therapeutic use in medication‐assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and t...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2018-01, Vol.103 (1), p.112-119
Main Author: Kraft, Walter K.
Format: Article
Language:English
Subjects:
Buprenorphine - pharmacology
Drug Dosage Calculations
Humans
Infant, Newborn
Narcotic Antagonists - pharmacology
Neonatal Abstinence Syndrome - drug therapy
Opiate Substitution Treatment - methods
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long‐acting opioid with therapeutic use in medication‐assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and treatment cohorts demonstrate the efficacy and safety of sublingual buprenorphine for those infants with NAS who require pharmacologic treatment. Pharmacometric modeling will assist in defining the exposure–response relationships and facilitate dose optimization.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.930